TY - JOUR
T1 - Induction of cell fusion/apoptosis in anaplastic thyroid carcinoma in orthotopic mouse model by urokinase-specific oncolytic Sendai virus
AU - Miyagawa, Yoshihiro
AU - Araki, Koji
AU - Yamashita, Taku
AU - Tanaka, Shingo
AU - Tanaka, Yuya
AU - Tomifuji, Masayuki
AU - Ueda, Yasuji
AU - Yonemitsu, Yoshikazu
AU - Shimada, Hideaki
AU - Shiotani, Akihiro
N1 - Funding Information:
Special Reseach Grant on Defense Medicine from the Ministry of Defense of Japan; and Japan Society for the Promotion of Science (JSPS) KAKENHI, Grant/Award Numbers: JP23592544, JP23592545, JP25462699, JP26462626, JP26462627, JP18K09390, JP17K11415, JP25670723, JP16K15726
Funding Information:
This work was supported by a Special Reseach Grant on Defense Medicine from the Ministry of Defense of Japan; and JSPS KAKENHI Grant Numbers JP23592544, JP23592545, JP25462699, JP26462626, JP26462627, JP18K09390, JP17K11415, JP25670723, JP16K15726 from Japan Society for the Promotion of Science.
Publisher Copyright:
© 2019 Wiley Periodicals, Inc.
PY - 2019/9
Y1 - 2019/9
N2 - Background: This study was designed to assess the therapeutic effect of urokinase-targeted recombinant oncolytic Sendai virus, termed “BioKnife,” on anaplastic thyroid carcinoma (ATC). Methods: Urokinase activity was investigated in human ATC cell lines, and BioKnife cytotoxicity against the cell lines was evaluated in vitro. Orthotopic mouse models of ATC were treated with three intratumoral injections of BioKnife, control virus, or phosphate-buffered saline (PBS) and were observed daily until >20% weight loss occurred. Results: All three ATC cell lines showed a high level of urokinase activity. BioKnife induced urokinase-dependent cell fusion and cytotoxicity in all cell lines. Orthotopic models treated with BioKnife showed significantly prolonged survival compared with models treated with control virus or PBS (BioKnife 41.6 ± 15.0, control virus 17.0 ± 2.9, PBS 17.7 ± 6.3 days). Conclusions: BioKnife exerted therapeutic effects in orthotopic ATC mouse models. Thus, BioKnife represents a possible treatment option for ATC.
AB - Background: This study was designed to assess the therapeutic effect of urokinase-targeted recombinant oncolytic Sendai virus, termed “BioKnife,” on anaplastic thyroid carcinoma (ATC). Methods: Urokinase activity was investigated in human ATC cell lines, and BioKnife cytotoxicity against the cell lines was evaluated in vitro. Orthotopic mouse models of ATC were treated with three intratumoral injections of BioKnife, control virus, or phosphate-buffered saline (PBS) and were observed daily until >20% weight loss occurred. Results: All three ATC cell lines showed a high level of urokinase activity. BioKnife induced urokinase-dependent cell fusion and cytotoxicity in all cell lines. Orthotopic models treated with BioKnife showed significantly prolonged survival compared with models treated with control virus or PBS (BioKnife 41.6 ± 15.0, control virus 17.0 ± 2.9, PBS 17.7 ± 6.3 days). Conclusions: BioKnife exerted therapeutic effects in orthotopic ATC mouse models. Thus, BioKnife represents a possible treatment option for ATC.
UR - http://www.scopus.com/inward/record.url?scp=85064173797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064173797&partnerID=8YFLogxK
U2 - 10.1002/hed.25769
DO - 10.1002/hed.25769
M3 - Article
C2 - 30969451
AN - SCOPUS:85064173797
VL - 41
SP - 2873
EP - 2882
JO - Head and Neck Surgery
JF - Head and Neck Surgery
SN - 1043-3074
IS - 9
ER -